Andrei R Shustov
Overview
Explore the profile of Andrei R Shustov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cassaday R, Zarling L, Garcia K, Sala-Torra O, Stevenson P, Martino C, et al.
Leuk Lymphoma
. 2023 Mar;
64(5):927-937.
PMID: 36938892
Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide,...
2.
Garcia K, Cherian S, Stevenson P, Martino C, Shustov A, Becker P, et al.
Cancer
. 2021 Dec;
128(7):1411-1417.
PMID: 34931301
Background: Potential involvement of the central nervous system (CNS) by acute lymphoblastic leukemia is typically evaluated by a conventional cytospin (CC) of cerebrospinal fluid (CSF). Multiparameter flow cytometry (MFC) is...
3.
Querfeld C, Thompson J, Taylor M, DeSimone J, Zain J, Shustov A, et al.
Lancet Haematol
. 2021 Oct;
8(11):e808-e817.
PMID: 34627593
Background: Intravenous TTI-621 (SIRPα-IgG1 Fc) was previously shown to have activity in relapsed or refractory haematological malignancies. This phase 1 study evaluated the safety and activity of TTI-621 in patients...
4.
Advani R, Skrypets T, Civallero M, Spinner M, Manni M, Kim W, et al.
Blood
. 2021 Jul;
138(3):213-220.
PMID: 34292324
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL...
5.
Falchi L, Ma H, Klein S, Lue J, Montanari F, Marchi E, et al.
Blood
. 2020 Nov;
137(16):2161-2170.
PMID: 33171487
Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We demonstrated in vitro synergism between histone deacetylase inhibitors and DNA methyltransferase inhibitors in preclinical models of T-cell lymphoma. In...
6.
Lansigan F, Horwitz S, Pinter-Brown L, Carson K, Shustov A, Rosen S, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Jun;
20(11):744-748.
PMID: 32532611
Introduction: We examined patient characteristics, treatments, and outcomes of patients with transformed mycosis fungoides (tMF) from COMPLETE: a large, multicenter, prospective cohort study of peripheral T-cell lymphoma patients in the...
7.
Fox C, Civallero M, Ko Y, Manni M, Skrypets T, Pileri S, et al.
Lancet Haematol
. 2020 Feb;
7(4):e284-e294.
PMID: 32105608
Background: Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological entity, typically associated with poor survival outcomes. Most published data have come from east Asian study groups, with...
8.
Halpern A, Howard N, Othus M, Hendrie P, Baclig N, Buckley S, et al.
Leukemia
. 2019 Oct;
34(2):635-639.
PMID: 31586148
No abstract available.
9.
OConnor O, Falchi L, Lue J, Marchi E, Kinahan C, Sawas A, et al.
Blood
. 2019 Sep;
134(17):1395-1405.
PMID: 31471376
The peripheral T-cell lymphomas (PTCLs) are uniquely sensitive to epigenetic modifiers. Based on the synergism between histone deacetylase inhibitors and hypomethylating agents that we established in preclinical PTCL models, we...
10.
Lansigan F, Horwitz S, Pinter-Brown L, Rosen S, Pro B, Hsi E, et al.
Acta Haematol
. 2019 Jul;
143(1):40-50.
PMID: 31315113
Background: Outcomes for patients with peripheral T-cell lymphoma (PTCL) who fail to achieve complete response (CR) or relapse after front-line therapy are poor with lack of prospective outcomes data. Objectives:...